Results of Switching from Tofacitinib to Upadacitinib in Patients with Atopic Dermatitis: A Retrospective Medical Record Review

Guttman-Yassky E , Thaçi D , Pangan AL , et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol, 2020; 145(3):–.

Suh TP , Ramachandran D , Patel V , et al. Product of investigator global assessment and body surface area (IGAxBSA): a practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children. J Am Acad Dermatol, 2020; 82(5):1187–1194. doi:.

AbbVie. RINVOQTM (upadacitinib) achieved superiority versus DUPIXENT® (dupilumab) for primary and all ranked secondary endpoints in phase 3b head-to-head study in adults with atopic dermatitis [press release]. December 10, 2020. Available at: https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-achieved-superiority-versus-dupixent-dupilumab-for-primary-and-all-ranked-secondary-endpoints-in-phase-3b-head-to-head-study-in-adults-with-atopic-dermatitis.htm. Accessed February 5, 2021.

Levy LL , Urban J , King BA . Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol, 2015; 73(3):395–399.

Mohamed MF , Beck D , Camp HS , et al. Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib. J Clin Pharmacol, 2020; 60(2):188–197.